1. Inicio
  2. Publicaciones
  3. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU.

Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Mesonero, Francisco
  • Zabana, Yamile
  • Fernandez-Clotet, Agnes
  • Leo-Carnerero, Eduardo
  • Caballol, Berta
  • Nunez-Ortiz, Andrea
  • Garcia, Maria Jose
  • Bertoletti, Federico
  • Suris, Gerard
  • Casis, Begona
  • Ferreiro-Iglesias, Rocio
  • Calafat, Margalida
  • Jimenez, Itxaso
  • Miranda-Bautista, Jose
  • Lamuela, Luis Javier
  • Fajardo, Ingrid
  • Torrealba, Leyanira
  • Najera, Rodrigo
  • Saiz-Chumillas, Rosa Maria
  • Gonzalez, Irene
  • Vicuna, Miren
  • Gutierrez, Ana
  • Lopez-Garcia, Alicia
  • Benitez, Jose Manuel
  • Rubin de Celix, Cristina
  • Tejido, Coral
  • Brunet, Eduard
  • Hernandez-Camba, Alejandro
  • Suarez, Cristina
  • Rodriguez-Lago, Iago
  • Piqueras, Marta
  • Castano, Andres
  • Ramos, Laura
  • Sobrino, Ana
  • Rodriguez-Grau, Maria Carmen
  • Elosua, Alfonso
  • Montoro, Miguel
  • Baltar, Ruth
  • Huguet, Jose Maria
  • Hermida, Benito
  • Caballero-Mateos, Antonio
  • Sanchez-Guillen, Luis
  • Bouhmidi, Abdel
  • Pajares, Ramon
  • Baston-Rey, Iria
  • Lopez-Sanroman, Antonio
  • Albillos, Agustin
  • Barreiro-de Acosta, Manuel

Grupos

Abstract

Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders. Design: This was a retrospective and multicentre study. Methods: We included patients diagnosed with inflammatory pouch disorders treated with azathioprine in monotherapy. Effectiveness was evaluated at 1year and in the long term based on normalization of stool frequency, absence of pain, faecal urgency or fistula discharge (clinical remission), or any improvement in these symptoms (clinical response). Endoscopic response was evaluated using the Pouchitis Disease Activity Index (PDAI). Results: In all, 63 patients were included [54% males; median age, 49 (28-77)years]. The therapy was used to treat pouchitis (n=37) or Crohn's disease of the pouch (n=26). The rate of clinical response, remission and non-response at 12months were 52%, 30% and 18%, respectively. After a median follow-up of 23months (interquartile range 11-55), 19 patients (30%) were in clinical remission, and 45 (66%) stopped therapy. Endoscopic changes were evaluated in 19 cases. PDAI score decreased from 3 (range 2-4) to 1 (range 0-3). In all, 21 patients (33%) presented adverse events and 16 (25%) needed to stop therapy. Conclusion: Azathioprine may be effective in the long term for the treatment of inflammatory pouch disorders and could be included as a therapeutic option.

© The Author(s), 2024.

Datos de la publicación

ISSN/ISSNe:
1756-283X, 1756-2848

Therapeutic Advances in Gastroenterology  SAGE Publications

Tipo:
Article
Páginas:
-
Factor de Impacto:
1,191 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • azathioprine; immunosuppressants; pouchitis; thiopurines

Campos de estudio

Proyectos asociados

ENSAYO SIMBA: SIMVASTATINA EN LA PREVENCIÓN DE PANCREATITIS AGUDA RECURRENTE: ENSAYO CLÍNICO TRIPLE CIEGO CONTROLADO CON PLACEBO.

Investigador Principal: ADOLFO DEL VAL ANTOÑANA

SIMBA-16 . 2017

EFECTO DE FLUIDOTERAPIA AGRESIVA FRENTE A FLUIDOTERAPIA BASADA EN METAS EN LA FASE PRECOZ DE LA PANCREATITIS AGUDA: ENSAYO CLÍNICO CONTROLADO ALEATORIZADO MULTICÉNTRICO.

Investigador Principal: MARÍA DOLORES HIGON BALLESTER

WATERFALL . 2019

Ensayo de fase IIa, aleatorizado, doble ciego y comparado con placebo para evaluar la seguridad, la eficacia, la farmacocinética y la farmacodinámica de BI 706321 administrado por vía oral durante 12 semanas en pacientes con enfermedad de Crohn (EC) que reciben tratamiento de inducción con ustekinumab.

Investigador Principal: MARIAM AGUAS PERIS

1425-0003 . 2023

Medicina de precisión en la enfermedad inflamatoria intestinal: predictores inmunológicos, genéticos y microbiológicos de respuesta a fármacos biológicos e inhibidores de la JAK-quinasa.

Investigador Principal: ALEJANDRO MÍNGUEZ SABATER

Medicina de precisión . 2023

Estudio de fase IIb aleatorizado, doble ciego y de determinación de dosis, de 14 semanas de duración, para determinar la farmacocinética, la eficacia, la seguridad y la tolerabilidad de TEV-48574 en pacientes adultos con colitis ulcerosa o enfermedad de Crohn moderada o grave (RELIEVE UCCD).

Investigador Principal: MARISA IBORRA COLOMINO

TV48574-IMM-20036 . 2023

A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.

Investigador Principal: MARISA IBORRA COLOMINO

ABX464-105 . 2024

Estudio de fase III aleatorizado, doble ciego y multicéntrico para evaluar la eficacia y la seguridad a largo plazo de ABX464 25 mg o 50 mg administrado una vez al día como tratamiento de mantenimiento en sujetos con colitis ulcerosa activa moderada o grave – ABTECT Maintenance.

Investigador Principal: MARISA IBORRA COLOMINO

ABX464-107 . 2024

Cita

Compartir